MabGenesis
5 known investors
MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. Using its MOURA antibody library and IMPACT high-efficiency monoclonal antibody isolation technology, it targets high-unmet-need areas such as cancer and zoonotic diseases, and has built dog and cat antibody libraries for the veterinary drug market.
Investors · 5
Also in the syndicate · 3
Axil Capital PartnersMiyazaki Taiyo CapitalREVIC Capital
In the news
Frequently asked questions
- What does MabGenesis do?
- MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. Using its MOURA antibody library and IMPACT high-efficiency monoclonal antibody isolation technology, it targets high-unmet-need areas such as cancer and zoonotic diseases, and has built dog and cat antibody libraries for the veterinary drug market.
- Who are MabGenesis's investors?
- MabGenesis's investors include Beyond Next Ventures, Long Black Partners.